Literature DB >> 9879164

Peak plasma concentrations after oral morphine: a systematic review.

S L Collins1, C C Faura, R A Moore, H J McQuay.   

Abstract

We performed a systematic review of 69 studies with information on 2146 subjects (454 patients and 1692 healthy volunteers) to examine the maximum plasma concentration (Cmax) and the time taken to reach maximum concentration (Tmax) for different oral morphine formulations, and to clarify factors contributing to variability. Data from healthy volunteers reflected that seen for patients but was less variable. There was minimal difference between single and multiple doses, suggesting no accumulation of morphine. For immediate-release morphine there was no difference in either dose-corrected Cmax or Tmax between solution and tablets, or between different salts. For controlled-release formulations, little difference was observed between brands. Only for once-daily formulations was there any difference in absorption between fed and fasted, with a Tmax for fed subjects considerably longer than for fasted. There was no evidence for any difference between values obtained by radioimmunoassay (RIA) or high-performance liquid chromatography (HPLC).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879164     DOI: 10.1016/s0885-3924(98)00094-3

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  28 in total

1.  Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.

Authors:  Lukas Radbruch; Luis M Torres; John E Ellershaw; Antonio Gatti; Guillermo Luis Lerzo; Julia Revnic; Donald Taylor
Journal:  Support Care Cancer       Date:  2011-03-22       Impact factor: 3.603

Review 2.  The role of opioids in cancer pain.

Authors:  Columba Quigley
Journal:  BMJ       Date:  2005-10-08

3.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 4.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-22

5.  A Pharmacokinetic-Pharmacodynamic Model of Morphine Exposure and Subsequent Morphine Consumption in Postoperative Pain.

Authors:  Rasmus Vestergaard Juul; Joakim Nyberg; Trine Meldgaard Lund; Sten Rasmussen; Mads Kreilgaard; Lona Louring Christrup; Ulrika S H Simonsson
Journal:  Pharm Res       Date:  2016-01-11       Impact factor: 4.200

6.  Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.

Authors:  John D Hoekman; Rodney J Y Ho
Journal:  Anesth Analg       Date:  2011-06-27       Impact factor: 5.108

7.  Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Authors:  Patrick A Singleton; Nurbek Mambetsariev; Frances E Lennon; Biji Mathew; Jessica H Siegler; Liliana Moreno-Vinasco; Ravi Salgia; Jonathan Moss; Joe Gn Garcia
Journal:  J Angiogenes Res       Date:  2010-02-19

8.  A randomized controlled trial of postoperative analgesia following total knee replacement: transdermal Fentanyl patches versus patient controlled analgesia (PCA).

Authors:  M J Hall; S M Dixon; M Bracey; P MacIntyre; R J Powell; A D Toms
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-03-11

9.  Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.

Authors:  James P Zacny; Stephanie A Lichtor
Journal:  Psychopharmacology (Berl)       Date:  2007-09-27       Impact factor: 4.530

Review 10.  Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research.

Authors:  Neil A Hagen; Patricia Biondo; Carla Stiles
Journal:  Curr Pain Headache Rep       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.